Boehringer Ingelheim has entered into a strategic partnership with Boston-based startup Rectify to develop oral medications targeting chronic kidney disease, a collaboration valued at up to $448 million in biobucks. This significant investment underscores Boehringer’s commitment to addressing unmet needs in renal therapeutics, particularly as the prevalence of chronic kidney disease continues to rise globally.
The partnership not only enhances Boehringer’s portfolio in the renal space but also elevates Rectify’s profile as an innovative player in the pharmaceutical landscape. By leveraging Rectify’s expertise in drug formulation and development, Boehringer aims to expedite the creation of effective treatments that could transform patient outcomes. This collaboration reflects a broader trend in the industry where established firms are increasingly seeking to partner with agile startups to drive innovation and bring novel therapies to market.
Start your 7-day trial and see what the database can do →
